ArticleJournal of nanobiotechnology2025
A novel scalable method for the production of rennet-treated milk-derived extracellular vesicles for improved curcumin oral delivery.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Bovine Milk-Derived Extracellular Vesicles as Emerging Drug Delivery Platforms: Current Advances, Applications and Challenges.Journal of extracellular biology · 2026Review
- Oral milk-derived exosomes loaded with tafatinib for anti-inflammatory therapy.International journal of pharmaceutics: X · 2026Article
- The Mechanistic Review of the Molecular Interface of RNA-Loaded Extracellular Vesicles: Redefining Targeted Therapy for Autoimmune Disorders.International journal of molecular sciences · 2026Review
- Pannexin-1 is present in a subpopulation of bovine milk-derived small extracellular vesicles.Cell and tissue research · 2026Article
- Interplay of Interleukin-1Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundExtracellular vesicles (EVs) are lipid bilayer-enclosed nanoparticles secreted by all cell types and are gaining increasing attention as natural, biocompatible drug delivery nanovehicles. Among the various sources, bovine milk-derived EVs (MEVs) represent an abundant, cost-effective, and eco-friendly alternative, with demonstrated potential in delivering chemotherapeutics, bioactive natural compounds, miRNAs, and other therapeutic agents. However, the effective and scalable production of MEVs still requires protocol optimization for contaminant removal, especially casein micelles and fat globules, which may be co-isolated and compromise EV quality. This study aimed to identify an efficient and scalable strategy for MEV production suitable for oral drug delivery applications.
resultsThree casein removal methods, acetic acid precipitation, ultracentrifugation, and commercial rennet, each combined with ultrafiltration/size exclusion chromatography (UF/SEC) for EV isolation were compared. Rennet treatment outperformed the other methods, yielding MEVs with superior purity, integrity, and minimal aggregation. MEVs with high quality and purity from whey derived from rennet-treated bovine milk successfully isolated by tangential flow filtration (TFF), a method more suitable for large-scale production. These vesicles were subsequently employed for the passive loading of curcumin, a hydrophobic compound with known bioactive properties but poor intrinsic bioavailability. The resulting curcumin-loaded MEVs (CurMEVs) were evaluated for their ability to traverse the intestinal barrier using in vitro and in vivo models. In addition, a prolongevity effect was observed in Caenorhabditis elegans animals supplemented with CurMEVs. Results confirmed that MEVs enhance curcumin stability and bioavailability.
conclusionsOur findings support the use of rennet combined with SEC or TFF to produce MEVs as scalable, safe, and effective delivery systems, offering a promising platform for future nutraceutical and pharmaceutical applications. In parallel, the study highlights the added value of converting dairy industry by-products, such as whey, into a sustainable source of nanocarriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.